REVELATION BIOSCIENCES INC
REVBNASDAQ🏆 #3878 by market capEarnings Nov 4US Equity
$1.13▲ $0.03 (+2.27%)
Live1h—
24h▲ 2.3%
7d▲ 2.3%
14d▲ 18.4%
30d▲ 13.1%
1y▼ 88.5%
🏦Market Cap
$4M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
60
Fair
Trading Snapshot
- Day Range
- $1.11 – $1.14
- 52-Week Range
- $0.88 – $11.72
- Volume
- $2.78B
- Avg Volume
- $2.50B
- Shares Outstanding
- 3.9M
- Next Earnings
- Sep 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $330,733
- Last Q Revenue
- $87,268
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-17.64
- Dividend Yield
- —
Why Investors Own REVB
- ✓High-growth profile — revenue up +41.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 51% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$330,733▲ +38.5% YoY
Gross Margin (TTM)
51.2%▲ +4.3% YoY
Operating Income (TTM)
$52,587▲ +38.5% YoY
Free Cash Flow (TTM)
$82,683▲ +38.5% YoY
About REVELATION BIOSCIENCES INC
A company profile for REVELATION BIOSCIENCES INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
60/100
Analyst Price Target
ⓘAverage Target
$1.08
▼ −3.7% Downside
High Target$1.24
Low Target$0.94
Based on 35 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
REVELATION BIOSCIENCES INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift REVB price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Barron’s·1d ago
REVELATION BIOSCIENCES INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.